VERTEX PHARMACEUTICALS INC

Vertex Pharmaceuticals’ $485/share surge follows FDA approval of a new CF drug and the acquisition of CRNX, boosting its biotech pipeline and investor confidence.

Vertex’s $10 B takeover of Crinetics expands its portfolio into endocrinology, adding Phase III assets and boosting revenue potential.

Vertex Pharmaceuticals hits a 52‑week high at $529.14, showcasing strong growth and investor confidence while advancing breakthrough treatments in cystic fibrosis and cancer.

Vertex expands CASGEVY gene‑therapy to children as young as two, offering earlier treatment for sickle cell and β‑thalassemia while boosting market reach and investor confidence.

Explore Vertex Pharmaceuticals’ latest breakthroughs in cystic fibrosis and cancer, market trends, and investment insights—discover how the Boston‑based biotech leader shapes global healthcare.

Vertex Pharmaceuticals faces board reshuffle, analyst cut to $437, and mixed market sentiment—discover what this means for investors.

Vertex Pharmaceuticals’ market performance and strategic positioning analyzed: strong cystic‑fibrosis pipeline, valuation risks, and diversification strategy for investors.

Vertex Pharmaceuticals eyes a 73% EPS jump and $13.02 bn revenue outlook, positioning the biotech leader for a potential upside in valuation and investor returns.

Vertex Pharmaceuticals officer buys 35k shares under SEC‑approved rule, raising holdings to ~35,000 shares in a March 2026 Form 4 filing.

Vertex Pharmaceuticals reports $12B 2025 revenue, 33% EPS gain, and 2026 growth plans, plus orphan drug approval for myasthenia gravis—strong biopharma outlook.